Diabetes: Lower risk of cardiovascular death with canagliflozin


Patients with type 2 diabetes mellitus have an increased risk of cardiovascular and renal disease. The CANVAS Program Collaborative Group sought to determine the cardiovascular safety and efficacy of canagliflozin, a sodium–glucose cotransporter 2 inhibitor, by combining data from two trials (CANVAS and CANVAS-R) involving 667 centres across 30 countries… (More)
DOI: 10.1038/nrcardio.2017.98


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics